What one share of Rallybio holds
We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.
Rallybio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.11 |
|---|---|
| Profit | $7.99 |
| Cash and investments | $17.50 |
| Book value | $17.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$12.17 | $0.06 | −$10.20 | — | $46.48 |
| 2021 | — | −$14.74 | $0.10 | −$14.38 | — | $43.72 |
| 2022 | — | −$16.76 | $0.01 | −$14.41 | — | $35.80 |
| 2023 | — | −$14.75 | $0.00 | −$11.92 | — | $22.46 |
| 2024 | $0.12 | −$10.61 | $0.00 | −$9.05 | — | $11.88 |
| 2025 | $0.15 | −$1.59 | — | — | — | $10.97 |
Common questions about Rallybio
How much does one share of Rallybio earn?
Over the last 12 months, each share of Rallybio earned $7.99 of profit on $0.11 of sales, keeping about 7050¢ of every $1 (profit margin).
Does Rallybio pay a dividend?
Rallybio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Rallybio’s book value per share?
Rallybio’s book value is $17.81 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Rallybio have?
Each share of Rallybio has $17.50 of cash and investments, as of June 30, 2026.
Has Rallybio bought back shares?
Rallybio’s share count rose about 159% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.